Novel Therapy May Be the First Line Treatment for Multiple Myeloma but Should Not Be the Last Word: Two Cases Illustrated

Abstract

Over the past 20 years, the treatment for multiple myeloma (MM) has evolved significantly. These pharmaceutical developments allow physicians to combine existing chemotherapy with newly approved novel and targeted medications to create various treatment regimens for MM. These novel drug combinations, immunomodulatory drugs (Thalidomide, lenalidomide and Pomalidomide) and proteasome inhibitors (Bortezomib and carfilzomib), are used upfront for induction therapy as well as for maintenance and treatment of subsequent relapses. However, the emergence of resistant myeloma clones to these drugs is usually inevitable. We describe 2 cases here that demonstrate beneficial response to old traditional chemotherapy combinations after patients become resistant to all novel drugs available. Therefore, our main message is that while novel drugs should be used in frontline combinations to treat MM patients, these novel drugs should not be the last word, and often going back to the old traditional chemotherapy may illicit response and possibly prolong survival.

Authors and Affiliations

Lindsay McCullough, Amy C. Davis, Issam Hamadeh, Ashley Richards, Jan S. Moreb

Keywords

Related Articles

A Rare Coexistence; Scaphoid and Triquetral Fracture without Perilunate Dislocation

The scaphoid is the most commonly fractured carpal bone, accounting for approximately 68 % of all carpal fractures. Triquetral fractures are the second most common carpal bone fracture and are usually ligamentous avulsio...

Neuroendocrine Tumour of the Appendix: A Case Report and Review of Literature

Neuroendocrine tumour of the appendix is a rare neoplasm discovered only incidentally. We hereby report an occurrence of this tumour in the appendix of a 27 years old female. There was an initial diagnosis of acute appen...

The Histological Diversities of Granular Cells in Ameloblastoma- A Diagnostic Quandary

Granular cells are the histological components in various odontogenic and non-odontogenic tumors of the oral cavity. Among the odontogenic tumors they are seen in granular cell ameloblastoma, plexiform granular cell odon...

Squamous Cell Carcinoma of the Larynx with Syndrome of Inappropriate Secretion of Antidiuretic Hormone

Background: Paraneoplastic syndromes result from the secretion of hormones by a tumor giving rise to different syndromes. Lung carcinomas are the most common tumors causing paraneoplastic syndromes. The most common is th...

An Unusual Case of Acute Myopericarditis Possibly Due to Food Poisoning

The manuscript describes the case of a 23 year-old woman, with acute myopericarditis associated with food poisoning without other cardiovascular disease. The patient had a history of hypothyroidism, treated with levothyr...

Download PDF file
  • EP ID EP328347
  • DOI 10.9734/IJMPCR/2016/26538
  • Views 103
  • Downloads 0

How To Cite

Lindsay McCullough, Amy C. Davis, Issam Hamadeh, Ashley Richards, Jan S. Moreb (2016). Novel Therapy May Be the First Line Treatment for Multiple Myeloma but Should Not Be the Last Word: Two Cases Illustrated. International Journal of Medical and Pharmaceutical Case Reports, 7(3), 1-7. https://europub.co.uk/articles/-A-328347